Author

David J. Warren

THE DEVELOPMENT AND VALIDATION OF A HIGH-CAPACITY SEROLOGICAL ASSAY FOR COELIAC DISEASE
THE DEVELOPMENT AND VALIDATION OF A HIGH-CAPACITY SEROLOGICAL ASSAY FOR COELIAC DISEASE

David J. Warren  et al.

SCREENING FOR ADULT COELIAC DISEASE IN THE GENERAL POPULATION
SCREENING FOR ADULT COELIAC DISEASE IN THE GENERAL POPULATION

David J. Warren  et al.

IMMUNOGENICITY AND SAFETY OF A THREE-DOSE SARS-COV-2 VACCINATION STRATEGY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY
IMMUNOGENICITY AND SAFETY OF A THREE-DOSE SARS-COV-2 VACCINATION STRATEGY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY

David J. Warren  et al.

SEROLOGIC RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNOSUPPRESSIVE THERAPY: ASSOCIATION TO DISEASE TYPE AND SERUM DRUG LEVELS
SEROLOGIC RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNOSUPPRESSIVE THERAPY: ASSOCIATION TO DISEASE TYPE AND SERUM DRUG LEVELS

David J. Warren  et al.

THE PERSISTENCE OF ANTI-SPIKE ANTIBODIES FOLLOWING TWO SARS-COV-2 VACCINES IN PATIENTS WITH INFLAMMATORY BOWEL- AND JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPY COMPARED TO HEALTHY CONTROLS – A PROSPECTIVE COHORT STUDY
THE PERSISTENCE OF ANTI-SPIKE ANTIBODIES FOLLOWING TWO SARS-COV-2 VACCINES IN PATIENTS WITH INFLAMMATORY BOWEL- AND JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPY COMPARED TO HEALTHY CONTROLS – A PROSPECTIVE COHORT STUDY

David J. Warren  et al.

FOUR SARS-COV-2 VACCINE DOSES OR HYBRID IMMUNITY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPIES. A PROSPECTIVE, OBSERVATIONAL COHORT STUDY
FOUR SARS-COV-2 VACCINE DOSES OR HYBRID IMMUNITY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPIES. A PROSPECTIVE, OBSERVATIONAL COHORT STUDY

David J. Warren  et al.

PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL
PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL

David J. Warren  et al.

Item 1 - 7 / 7
1